CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

• Published in: Cancer Immunology, Immunotherapy Vol. 70; no. 6; pp. 1781 - 1788
• Main Authors: Fietz, Simon, Zarbl, Romina, Niebel, Dennis, Posch, Christian, Brossart, Peter, Gielen, Gerrit H., Strieth, Sebastian, Pietsch, Torsten, Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2021; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Biomarkers, Tumor - genetics; Cancer Research; CTLA-4 Antigen - genetics; CTLA-4 protein; DNA Methylation; Epigenetics; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immune checkpoint; Immunohistochemistry; Immunology; Immunotherapy; Ipilimumab - therapeutic use; Lymphocytes; Male; Medicine; Medicine & Public Health; Melanoma; Melanoma - drug therapy; Melanoma - mortality; Melanoma - pathology; Middle Aged; Monoclonal antibodies; Oncology; Prognosis; Promoter Regions, Genetic; Protein expression; Proteins; Research Report; Retrospective Studies; Survival Rate; Targeted cancer therapy; Tumor cells; Tumors; DNA methylation; CTLA-4; Immunotherapy; Predictive biomarker; Melanoma; CTLA4

Anti-CTLA-4-antibodies can induce long-lasting tumor remissions. However, only a few patients respond, necessitating the development of predictive companion biomarkers. Increasing evidence suggests a major role of epigenetics, including DNA methylation, in immunology and resistance to immune checkpo...